CERE Cerevel Corp: Market Value

Public company logo of Cerevel Therapeutics, Inc. (CERE)

This price chart for Cerevel Therapeutics (CERE) on the GURU.Markets platform reflects a sovereign development cycle, rendering the asset a defensive asset due to stable demand for healthcare. The business focuses on developing therapies to combat Parkinson's disease and schizophrenia, targeting the massive CNS market. However, geopolitical tensions and sanctions complicate component logistics, which slows down drug registration, and the metric stands at 8.19.

Cerevel Therapeutics, Inc. - CERE Market Value (period 07/04/2022 - 08/10/2024)

CERE (Cerevel Therapeutics, Inc.): analytical breakdowns and indicator data

- current price and projected stock value:
Stock Price cerevel.com|CERE - Average Forecast Price
- company stock capitalization data:
Market Value Cerevel Therapeutics Inc|CERE - Value Adjusted for Debt and Cash
- book value of equity indicators:
Book Value per Share Cerevel Therapeutics|CERE - Total Stockholders' Equity|Market Value to Book Value Ratio cerevel.com|CERE - Total Business Assets
- debt and solvency information:
Total Debt to Capital Cerevel Therapeutics|CERE - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio cerevel.com|CERE - Company Aggregate Debts|Debt to Book Capitalization Ratio Cerevel Therapeutics Inc|CERE - Company Long-Term Loans and Borrowings|Company Short-Term Debt Cerevel Therapeutics|Quick Ratio cerevel.com
- financial results and valuation multiples details:
CERE - Net Income|Projected Future Earnings Cerevel Therapeutics|CERE - Market Cap to Earnings|Future Price to Earnings Cerevel Therapeutics|CERE - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Cerevel Corp|CERE - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Cerevel Therapeutics|CERE - Earnings per share for the last twelve months|Quarterly EPS earnings growth cerevel.com|CERE - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Cerevel Therapeutics
- revenue and sales details:
CERE - Company Revenue|Company Future Sales Volume Cerevel|CERE - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Cerevel Corp
Fundamental company analysis:CERE (Cerevel)
Product sample of cerevel.com

Cerevel Therapeutics specializes in developing innovative therapies for central nervous system diseases. The dynamics of the issuer's market capitalization reflect the market's valuation of the success of these clinical developments. This figure is calculated as the product of the current share price and the total number of outstanding securities. This metric determines the total value of the equity capital and the financial weight of the enterprise. Analyzing this indicator allows for an assessment of the company's investment attractiveness within the biotechnology sector.

Key competitors

Market Capitalization BIIB (Biogen Idec)|Neurocrine Biosciences Inc - Market Value|regencellbioscience.com - Market Capitalization|Market Capitalization axsome.com AXSM|ACAD: Market Capitalization|Market Value Xenon Pharmaceuticals Inc. (XENE)|Market Value Viking Therapeutics|Market Capitalization SUPN (Supernus Pharma)|Market Capitalization CPRX|DNLI - Market Value|harmonybiosciences.com - Market Valuation|Market Capitalization Biohaven Ltd BHVN|AMLX - Market Value|Market Value TRVI (Trevi Corp)|Praxis Precision Medicines Inc (PRAX) - Market Value|Market Value Anavex Life Sciences (AVXL)|CBLL (CeriBell Inc) - Market Capitalization|Prothena Corporation - Market Valuation|Market Value Alector (ALEC)|Annexon Biosciences Inc. - Market Capitalization|Market Capitalization OMER (Omeros)|Market Capitalization neurogene.com NGNE|AC Immune S.A. - Market Capitalization|VYGR - Market Capitalization|neumoratx.com (NMRA) - Market Value|Market Value Scilex Holding Company (SCLX)|TVGN (Tevogen Bio Holdings Inc.) - Market Capitalization|ACOG: Market Value|Market Capitalization CGTX|Market Capitalization Inhibikase Therapeutics Inc (IKT)|Cassava - Market Valuation|assertiotx.com (ASRT) - Market Value|COYA - Market Value|Market Value VTGN (VistaGen Therapeutics, Inc.)|OVID: Market Capitalization|Acumen Pharmaceuticals Inc. (ABOS) - Market Capitalization|Market Value CervoMed Inc.|ATHE: Market Value|Market Value Clene (CLNN)|PEPG: Market Valuation|Market Value Jupiter Neurosciences, Inc. JUNS|Market Capitalization Relmada Therapeutics Inc RLMD|ANVS - Market Value|GRCE - Market Capitalization|AIFF: Market Capitalization|KLTO - Market Capitalization|NRSN (NeuroSense Therapeutics, Ltd.) - Market Capitalization|Market Capitalization Reviva Pharmaceuticals Holdings|Market Capitalization MTVA|Market Capitalization NeurAxis Inc|Helius Medical Technologies - Market Valuation|Market Capitalization Passage Bio, Inc. PASG|NEUP: Market Valuation|Minerva Neurosciences, Inc. (NERV) - Market Valuation|ATHA (Athira Pharma) - Market Valuation|Market Capitalization ADXN|Market Value Alzamend Neuro, Inc.|Market Valuation cyclerion.com (CYCN)|Market Capitalization PTIX|Market Capitalization Pasithea (KTTA)|Market Value Cortigent CRGT|Market Capitalization Avenue Therapeutics Inc (ATXI)|BCLI - Market Value|CARA - Market Capitalization|CHRO: Market Capitalization|Eliem (ELYM) - Market Capitalization|Market Valuation ITCI|Market Value LBPH|Market Value marinuspharma.com (MRNS)|NKGN - Market Value|Market Value NeuroBo NRBO|Sage Therapeutics, Inc (SAGE) - Market Value|SNPX - Market Value|Market Value TRVN (Trevena, Inc)|VIGL: Market Capitalization|Market Valuation Anew Medical, Inc.